Posted by Surbhi on July 09 2026 at 06:02 PM
public
IL-23 inhibitors in IBD treatment — the selective biologics targeting the p19 subunit of interleukin-23 (risankizumab/Skyrizi, guselkumab/Tremfya, mirikizumab/Omvoh) demonstrating superior effica...
The Wound Care Biologics Market was valued at US$ 5.87 Billion in 2025 and is projected to reach US$ 9.42 Billion by 2033, registering a CAGR of 6.09% during 2026–2033. This master version evalua...
Posted by Adam aam on October 08 2026 at 02:18 PM
public
The inflammatory bowel disease biologics market is forecast to expand from USD 60.73 billion in 2026 to USD 130.81 billion by 2036, registering an 8.0% CAGR over the forecast period. Fact.MR attr...
Posted by Adam aam on September 26 2026 at 01:44 PM
public
Rockville, MD., September 26, 2026 — The Targeted Oncology Biologics Market is projected to grow from USD 71.01 billion in 2026 to USD 162.04 billion by 2036, advancing at a 8.6% CAGR during the ...
Sports Medicine Biologics Market: Growth, Trends, Demand & Forecast to 2034
Sports Medicine Biologics Market Overview
The Sports Medicine Biologics Market is expanding as athletes, sports m...